In ex vivo studies, Feng et al. showed that isatuximab can preferentially block Tregs and enhance NK and CD8+ T-effector cell-mediated immune responses, effectively restoring immune effector functions against MM cells [31]. This evidence concerns the gene CD8A and Miyoshi myopathy.